PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat

10 Görünümler
administrator
administrator
07/08/23

UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat

  • kategori

Daha fazla göster

0 Yorumlar Göre sırala

Hiçbir yorum bulunamadı

Facebook Yorumları

Bir sonraki